Focal laser photocoagulation of the optic disc peripapillary neovascularization in patient with proliferative diabetic retinopathy
https://doi.org/10.47183/mes.2022.004
Abstract
Diabetic retinopathy (DR) is one of the most common complications of diabetes mellitus and one of the major causes of blindness in the developed world. Retinal laser photocoagulation is a gold standard for the treatment of DR. Despite its high efficiency, laser therapy has a number of limitations. The emergence of drugs, designed to inhibit the growth of the newly formed blood vessels, in ophthalmic practice made it possible to change treatment strategy in patients with retinal neovascularization. However, this method also has some adverse effects. Given the limitations on the repeated sessions of laser photocoagulation and the risks of ophtalmic complications after the intravitreal injection of the angiogenesis inhibitors, extraordinary situations, when there are negative results of treatment with the use of the described above techniques in one eye and disease progression in the single eye with preserved vision, become a serious problem when performing treatment. The clinical case reported has shown the feasibility of staged laser treatment in patient with the optic disc peripapillary neovascularization. Therapy has resulted in the regression of the newly formed blood vessels and visual function preservation.
About the Authors
Kh. P. TakhchidiRussian Federation
Moscow.
N. Kh. Takhchidi
Russian Federation
Moscow.
T. A. Kasminina
Russian Federation
Moscow.
E. P. Tebina
Russian Federation
Ekaterina P. Tebina,
30, korp. 2, Volokolamskoe shosse, Moscow, 123182.
References
1. Stewart MW.Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes. 2016; 7 (16): 333–341.
2. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009; 116 (3): 497–503.
3. Sergushev SG, Homjakova EN. Anti-VEGF preparaty v terapii pacientov s diabeticheskim makuljarnym otekom. Klinicheskaja oftal'mologija. 2019; 25 (4): 238–44. Russian.
4. Federal'nyi registr saharnogo diabeta RF, realizuemyĭ FGBU «NMIC ̆ jendokrinologii» Minzdrava Rossii. Dostupno po ssylke: https://www.endocrincentr.ru/sites/default/files/all/EVENTS2019/NEWS%20SUM/13.03.19%20Prof.komissia/VIK_Exp_13.03.19.pdf.
5. Smirnova OM. Diabeticheskaja retinopatija. Rezul'taty mezhdunarodnyh mnogocentrovyh issledovanij. Saharnyj diabet. 2010; 13 (1): 80–87. Russian.
6. Bosma EK, van Noorden CJF, Klaassen I, Schlingemann RO. Diabetic Nephropathy. Springer, 2019. DOI: 10.1007/978-3-31993521-8_19.
7. Burjakov DA, Kachalina GF, Pedanova EK, Kryl LA. Ocenka bezopasnosti povtornyh seansov subporogovogo mikroimpul'snogo lazernogo vozdeistvija pri lechenii diabeticheskogo makuljarnogo ̆ oteka. Sovremennye tehnologii v oftal'mologii. 2015; 3: 19–21. ̈ Russian.
8. Zajka VA, Shhuko AG, Arhipov EV, Bukina VV. Ocenka dolgosrochnoj jeffektivnosti panretinal'noj lazernoj koaguljacii pri saharnom diabete 2-go tipa. Sovremennye tehnologii v oftal'mologii. 2020; (1): 34–36. Russian.
9. Gacu MV, Bajborodov YaV. Kliniko-topograficheskaja klassifikacija diabeticheskih makulopatij. Saharnyj diabet. 2008; 11 (3): 20–22. Russian.
10. Jacob T. Cox, Dean Eliott, and Lucia Sobrin. Inflammatory Complications of Intravitreal Anti-VEGF Injections. J Clin Med. 2021; 10 (5): 981.
11. Yau JW, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; (35): 556–64.
Review
For citations:
Takhchidi Kh.P., Takhchidi N.Kh., Kasminina T.A., Tebina E.P. Focal laser photocoagulation of the optic disc peripapillary neovascularization in patient with proliferative diabetic retinopathy. Extreme Medicine. 2022;24(1):69-73. https://doi.org/10.47183/mes.2022.004